HCWB
What one share of HCW Biologics holds
Pharmaceutical Preparations
HCW Biologics Inc. (“HCW Biologics” or the “Company”) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. We have created novel compounds that represent a new class of drugs that we believe have the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia.
HCW Biologics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $8.50 |
|---|---|
| Profit | −$27.18 |
| Cash and investments | $0.40 |
| Debt | $3.71 |
| Book value | $4.04 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$358.23 | $9.45 | −$537.70 | — | −$846.63 |
| 2021 | — | −$164.46 | $0.60 | −$140.94 | — | $343.39 |
| 2022 | — | −$99.83 | $68.84 | −$138.43 | — | $250.31 |
| 2023 | — | −$166.96 | $41.43 | −$191.82 | — | $85.42 |
| 2024 | — | −$185.75 | $1.62 | −$89.64 | — | −$36.16 |
| 2025 | $0.16 | −$63.78 | $0.00 | −$38.30 | — | $2.46 |